Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risperidone and explosive aggressive autism

J P Horrigan1, L J Barnhill

  • 1Department of Psychiatry, University of North Carolina, Chapel Hill 27599-7160, USA.

Journal of Autism and Developmental Disorders
|June 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adderall, the atypicals, and weight gain.

Journal of the American Academy of Child and Adolescent Psychiatry·2001
Same author

Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder.

Expert opinion on pharmacotherapy·2001
Same author

Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder.

The Journal of clinical psychiatry·2000
Same author

Guanfacine and secondary mania in children.

Journal of affective disorders·1999
Same author

Alternative therapies in the child psychiatric clinic.

Journal of child and adolescent psychopharmacology·1999
Same author

Diet and the atypical neuroleptics.

Journal of the American Academy of Child and Adolescent Psychiatry·1998
Same journal

Motor Competence and Physical Fitness in Children and Adolescents With ADHD: A Comparative Study with Typically Developing Peers.

Journal of autism and developmental disorders·2026
Same journal

Assessing Camouflaging in Adolescence: Psychometric Evaluation of the German Camouflaging Autistic Traits Questionnaire (CAT-Q/DE).

Journal of autism and developmental disorders·2026
Same journal

Behavior Regulation Abilities in Children With Prader-Willi Syndrome and Their Impact on Daily Life: At the Crossroads of Cognitive and Emotional Development.

Journal of autism and developmental disorders·2026
Same journal

The Role of Peer Victimisation and Parental Mental Health in Internalising Problems: Examining Bidirectional Relationships Across Childhood and Adolescence in Autistic Youth.

Journal of autism and developmental disorders·2026
Same journal

An Analysis of the Psychometric Properties of the Pediatric Inventory for Parents: Short Form Among Caregivers of Children Diagnosed With Autism Spectrum Disorder.

Journal of autism and developmental disorders·2026
Same journal

A Scoping Review on Positive Emotions and Affect in Autism.

Journal of autism and developmental disorders·2026
See all related articles

Risperidone effectively treated aggression and explosivity in autistic patients with mental retardation. This study found significant improvements in behavior and sleep, with weight gain as the primary side effect.

Area of Science:

  • Neurodevelopmental disorders
  • Psychopharmacology
  • Autism Spectrum Disorder

Background:

  • Autistic patients with mental retardation often exhibit challenging behaviors like aggression and explosivity.
  • These behaviors can be resistant to traditional pharmacotherapeutic interventions.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of risperidone in treating aggression and explosivity in autistic male outpatients with mental retardation.

Main Methods:

  • An open-label study involving 11 male outpatients (mean age 18.3 years).
  • Risperidone was administered, starting at 0.5 mg daily and titrated to maximum clinical benefit.
  • Clinical interviews and Conners Parent-Teacher Questionnaires were used for assessment.

Main Results:

Related Experiment Videos

  • Immediate and substantial clinical improvement was observed in all patients.
  • Aggression, self-injury, explosivity, and poor sleep hygiene showed the most significant improvement.
  • The modal dose for optimal response was 0.5 mg twice daily.
  • Weight gain (average 0.47 kg/week) was a significant side effect; no extrapyramidal side effects were reported.

Conclusions:

  • Risperidone demonstrates significant efficacy in managing behavioral issues in autistic patients with mental retardation.
  • The medication appears well-tolerated, with weight gain being the main concern.
  • Further research into long-term effects and optimal dosing is warranted.